Robert Hazlett
Stock Analyst at BTIG
(0.49)
# 3,903
Out of 4,832 analysts
23
Total ratings
30%
Success rate
-26.42%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $4.90 | +389.80% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $0.72 | +459.44% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.56 | +2,414.37% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.11 | +17,805.10% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $103.67 | -5.47% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $7.13 | +741.51% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $3.86 | +1,532.12% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $6.89 | +321.21% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.88 | +1,382,878.72% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $2.45 | +144.90% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $11.34 | +58.73% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $4.90
Upside: +389.80%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $0.72
Upside: +459.44%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.56
Upside: +2,414.37%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.11
Upside: +17,805.10%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $103.67
Upside: -5.47%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $7.13
Upside: +741.51%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $3.86
Upside: +1,532.12%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $6.89
Upside: +321.21%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.88
Upside: +1,382,878.72%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $2.45
Upside: +144.90%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $11.34
Upside: +58.73%